March I, 2024

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

Camrelizumab, nab-paclitaxel, and cisplatin showed statistically significant enhancements in pathologic complete responses in patients with resectable locally advanced esophageal squamous cell carcinoma.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.

Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.

Technology plays a pivotal role in enhancing precision medicine within cancer care.

Health and Human Services leaders are “optimistic” about the future of artificial intelligence in medicine. However, they won’t trust without verifying.

Six CAR T-cell therapies have gained FDA approval across hematologic malignancy settings. These approvals have spurred further exploration for their use in solid tumors.